No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 1.4x · 10Y median 5.4x · 12th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 27
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T14:05:53.276Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Bolt Biotherapeutics, Inc. (BOLT) stock was $3.55 as of Oct 6, 2026, 9:43 AM EDT, up 1.43% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -34.0% · 3-year avg -43.1%/yr · 5-year avg -57.6%/yr
Bolt Biotherapeutics, Inc. is a biotechnology company currently conducting clinical trials, focused on developing innovative immuno-oncology therapies.
Biotechnology · Redwood City, CA
Next Earnings Date
Nov 11, 2026
36 days away
EPS Estimate
-3.89
Revenue Est.
$68333.00
Last Quarter Results
EPS
$-4.57
vs Estimate
$-3.39
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1BOLT | $6.82M | $3.55 | +1.43% | -33.96% | -57.61% | N/A | N/A |
| 2ACON | $6.80M | $2.36 | +0.77% | -68.01% | N/A | N/A | vs BOLT |
| 3KALA | $6.77M | $0.35 | -3.42% | -99.52% | -85.73% | N/A | vs BOLT |
| 4MGRX | $7.09M | $0.42 | N/A | -81.44% | N/A | N/A | vs BOLT |
| 5ENSC | $6.55M | $0.43 | +1.72% | -83.36% | -86.22% | N/A | vs BOLT |
| 6ENVB | $6.52M | $1.46 | -3.60% | N/A | N/A | N/A | vs BOLT |
forward FY estimate
N/A
$5000.00
vs Estimate
$500000.00
Consensus Rating
Based on 3 analysts
Average Price Target
$29.00
+716.9% upside
Low
$5.00
Current
$3.55
High
$75.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-3.89 | $-3.89 | $-3.89 | 1 |
| Quarter ending Dec 2026 | $-4.00 | $-4.00 | $-4.00 | 1 |
| Quarter ending Mar 2027 | $-2.00 | $-2.00 | $-2.00 | 1 |
| Quarter ending Jun 2027 | $-2.20 | $-2.20 | $-2.20 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-17.89 | $-17.89 | $-17.89 | 2 |
| FY 2027 | $-24.74 | $-20.19 | $-15.64 | 2 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $68333.00 | $68333.00 | $68333.00 | 2 |
| Quarter ending Dec 2026 | $51333.00 | $51333.00 | $51333.00 | 2 |
| Quarter ending Mar 2027 | $100000.00 | $100000.00 | $100000.00 | 1 |
| Quarter ending Jun 2027 | $100000.00 | $100000.00 | $100000.00 | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $133333.00 | $133333.00 | $133333.00 | 1 |
| FY 2027 | $3.50M | $3.50M | $3.50M | 2 |
